"When will KINTOR PHARMA-B (09939) reach a critical point for valuation reversal after the bottom consolidation and trend rebound?"

On September 7, before the market opened, KINTOR PHARMA-B (09939) announced that its self-developed novel highly efficient tyrosinase inhibitor KT-939, which suppresses melanin production, has successfully completed a long-term safety trial in humans as of September 4, 2026. Initial data show that after a continuous 52-week use of KT-939 by a total of 114 subjects, no skin adverse reactions were reported, consistent with the mid-trial clinical results after 28 weeks, demonstrating that KT-939 has good safety. Stimulated by this positive news, the stock price of Kintor Pharma quickly rose after the market opened, increasing by 9.89% within half an hour, with stock prices climbing back above 2 Hong Kong dollars. Since the disclosure of the 26H1 financial report on August 19, Kintor Pharmas stock price experienced a "bottoming out followed by a rebound" phase. The extent to which the companys stock price can rebound due to favorable news has become a focal point for investors. How far can the strong consolidation at the bottom and oversold recovery go? From May to July this year, despite the core pipeline KX-826's phase III clinical data being recognized at international conferences and its commercialization plan being ready, the overall liquidity in the Hong Kong stock market was tight, with a significant decrease in investors' risk appetite, leading to capital flow out of high-volatility growth sectors. This widespread valuation contraction had a considerable impact on Kintor Pharma, which relies on future cash flow. As a result, the companys stock price dropped nearly 50% during this period, being cut in half at one point. It wasnt until early August this year that the stock price benefited from the nearing key fundamental milestones, favorable industry policies, and a shift in market style, leading to a "six consecutive days of gains" from August 4 to 12. After a technical drop until August 31, it again entered a rebound phase. From the trading perspective, from August 31 to September 4, Kintor Pharma exhibited a strong consolidation structure with "increased volume at the start, moderate volume increase during the rise, extreme volume reduction during the pullback, and then aggressive volume increase in the rally." Specifically, the period from August 31 to September 3 was a typical active offensive phase. During this time, Kintor Pharma's daily trading volume increased from 2.188 million shares to 2.651 million shares, while the stock price also rose, clearly indicating a simultaneous increase in both volume and price. Subsequently, although the stock price of the company closed down 3.96% on September 4 and showed some pullback, the trading volume that day was only 851,000 shares, corresponding to 47.9% of the average daily trading volume in the range, with a turnover rate of only 0.17%. The decline in stock price accompanied by reduced volume may suggest that the funds in Kintor Pharma were not concentrated in an exit but rather showed strong consolidation. Overall, the average trading volume on rising days was about 2.5 times that of falling days, and the net volume of On-Balance Volume (OBV) increased from -4.143 million to 1.276 million, further indicating that the price rebounded alongside net capital inflow, with evident improvement in external capital support and not a rise without volume. The recent increase in volume and price for Kintor Pharma can also be cross-validated from a technical perspective. Between August 31 and September 6, the stock was clearly in an accelerated rebound phase from oversold, with multiple periods of moving averages showing bullish alignment. In terms of moving average performance, on a short-term basis, the 5-day and 10-day moving averages have turned upward and crossed above the 20-day moving average, while the 60-day moving average still presents mid-term pressure; in Bollinger Bands, the stock price rebounded from the lower band near the low of 1.60 Hong Kong dollars on August 28 to above the middle band, with consecutive touches on the upper band and subsequent pullbacks on September 3, 4, and 7, currently situated in the stronger area between the upper and middle bands. However, on September 7, although the companys stock price peaked at one point, the volume ratio was only 0.57, indicating that while the price reached a new local high, the trading volume showed significant shrinkage, suggesting a possible short-term momentum deceleration. Additionally, on the technical front, the RSI6 indicator for Kintor Pharma was 79.7 at the close on September 3, and on September 7, the indicator further rose to 82.4, presenting a scenario where the price did not create a new high while the RSI6 continued to rise, indicating a clear strengthening of momentum. However, the significant volume shrinkage on September 7 compared to September 3 raises concerns about a potential divergence between volume and price in the short term. When can long-term value be realized after short-term gains? From a fundamental performance perspective, the "beauty crossover" strategy of Kintor Pharma, which was previously questioned by the market, has matured in recent years. The reason the announcement made on September 7 triggered a notable market reaction is due to the mention of the product KT-939 in the announcement, as well as the high revenue growth expectations brought by KOSHIN/KT-939. KT-939 is independently developed by Kintor Pharma and is a tyrosinase inhibitor that efficiently suppresses melanin production, offering both antioxidant and anti-inflammatory effects. Previously, Kintor Pharma had publicly stated that KT-939 significantly outperformed current mainstream whitening ingredients in human cell tyrosinase inhibition experiments, cell melanin production experiments, and protein binding experiments. As early as September 2025, all subjects for KT-939 had been enrolled to begin a continuous 52-week skin safety test with a topical application of 0.2% KT-939. The interim results indicated that after 28 weeks of continuous use by a total of 119 subjects, no skin adverse reactions were reported, including cosmetic contact dermatitis, cosmetic photoallergic dermatitis, cosmetic-induced pigmentation disorders, cosmetic contact urticaria, and cosmetic acne. From a market perspective, data shows that by 2025, the retail sales of the whitening and spot-removing cosmetics market in China reached 128.93 billion yuan, growing by 20.6% year-on-year. The competition in this red ocean market has reached a fever pitch, and brands must tell new stories, which is one of the reasons why major companies are racing to layout new whitening ingredients. The 52-week data from the human long-term safety trial of KT-939 further validates the efficacy and safety of the product, allowing Kintor Pharma to establish its foothold in the fiercely competitive market for whitening materials/new products. However, compared to KT-939, the promotion of the NDA for the core product KX-826 and its subsequent commercialization may be the key support for Kintor Pharma's medium to long-term stock price elasticity. It is reported that on July 10, 2024, Kintor Pharma announced the market launch of cosmetics based on KX-826. Its first product is a topical anti-hair loss solution targeting androgenetic alopecia (AGA). It is evident that although this product is a cosmetic, it targets the same hair loss market as products for androgenetic alopecia. According to a research report by GrandViewResearch, the global hair loss treatment market was valued at $8.2 billion in 2022, and it is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2030, with the market size expected to reach $16.02 billion by 2030. According to Kintor Pharma's 26H1 financial report disclosed on August 19, the company's revenue increased from 6 million yuan in the same period last year to 52 million yuan for the six months ended June 30, 2026, with a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%. The increase in revenue was mainly due to sales driven by live e-commerce for the high-end cosmetics brand KOSHIN (of which KX-826 is one of the core ingredients). From the perspective of the company's product operational strategy, KX-826 is undoubtedly the core asset determining its valuation ceiling. This drug is not just a cosmetic ingredient but a potential First-in-Class topical AR antagonist, and once KX-826 is smoothly approved and released, it may push the market to switch Kintor Pharma's valuation logic from "small-cap loss Biotech + cosmetic sales" to "commercialization platform for innovative hair loss drugs." According to Kintor Pharma's previous plans, KX-826 is expected to submit its NDA in the second half of this year, with approval anticipated in the second half of 2027, and the company's goal is to "achieve high sales post-approval" with sales targets exceeding 100 million yuan. For investors who are bullish on this stock, now may very well be a significant juncture for betting on the smooth advancement of its medium to long-term plans.